Journal Publications

Export 124 results:
Author Title Type [ Year(Desc)]
Filters: Type is Journal Article  [Clear All Filters]
The impact of HIV drug resistance testing on changes to treatment. Bansi L, Smith C, Phillips A, Kirk S, Geretti A, Johnson M, Mackie N, Post F, Gazzard B, Dunn D et al. AIDS, 2011 Mar 13, Volume 25, Issue 5, p.603-10, (2011)
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T et al. Eur J Neurol, 2011 Mar, Volume 18, Issue 3, p.527-34, (2011)
Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease. Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T et al. Neurology, 2011 Feb 22, Volume 76, Issue 8, p.693-700, (2011)
Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception. Huntington S, Bansi L, Thorne C, Anderson J, Newell M, Taylor G, Pillay D, Hill T, Tookey P and Sabin C. AIDS, 2011 Aug 24, Volume 25, Issue 13, p.1647-55, (2011)
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Cain L, Logan R, Robins J, Sterne J, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F et al. Ann Intern Med, 2011 Apr 19, Volume 154, Issue 8, p.509-15, (2011)
Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score. Cozzi-Lepri A, Prosperi M, Kjær J, Dunn D, Paredes R, Sabin C, Lundgren J, Phillips A and Pillay D. PLoS One, 2011, Volume 6, Issue 11, p.e25665, (2011)
Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study. Barber T, Geretti A, Anderson J, Schwenk A, Phillips A, Bansi L, Gilson R, Hill T, Walsh J, Fisher M et al. Antivir Ther, 2011, Volume 16, Issue 6, p.805-14, (2011)
Baseline kidney function as predictor of mortality and kidney disease progression in HIV-positive patients. Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C and Post F. Am J Kidney Dis, 2012 Oct, Volume 60, Issue 4, p.539-47, (2012)
Biomarkers to monitor safety in people on art and risk of mortality. Bansi L, Gazzard B, Post F, Phillips A, Johnson M, Hill T, Gilson R, Leen C, Walsh J, Fisher M et al. J Acquir Immune Defic Syndr, 2012 May 01, Volume 60, Issue 1, p.51-8, (2012)
Evaluating the extent of potential resistance to pre-exposure prophylaxis within the UK HIV-1-infectious population of men who have sex with men. Dolling D, Phillips A, Delpech V, Pillay D, Cane P, Crook A, Shepherd J, Fearnhill E, Hill T and Dunn D. HIV Med, 2012 May, Volume 13, Issue 5, p.309-14, (2012)
Calendar time trends in the incidence and prevalence of triple-class virologic failure in antiretroviral drug-experienced people with HIV in Europe. Nakagawa F, Lodwick R, Costagliola D, van Sighem A, Torti C, Podzamczer D, Mocroft A, Ledergerber B, Dorrucci M, Cozzi-Lepri A et al. J Acquir Immune Defic Syndr, 2012 Mar 01, Volume 59, Issue 3, p.294-9, (2012)
Comparison of CKD-EPI and MDRD to estimate baseline renal function in HIV-positive patients. Ibrahim F, Hamzah L, Jones R, Nitsch D, Sabin C and Post F. Nephrol Dial Transplant, 2012 Jun, Volume 27, Issue 6, p.2291-7, (2012)
Using two on-going HIV studies to obtain clinical data from before, during and after pregnancy for HIV-positive women. Huntington S, Bansi L, Thorne C, Anderson J, Newell M, Taylor G, Pillay D, Hill T, Tookey P and Sabin C. BMC Med Res Methodol, 2012 Jul 28, Volume 12, p.110, (2012)
Non-uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/μL in the UK. Kober C, Johnson M, Fisher M, Hill T, Anderson J, Bansi L, Gompels M, Palfreeman A, Dunn D, Gazzard B et al. HIV Med, 2012 Jan, Volume 13, Issue 1, p.73-8, (2012)
Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy? Gompels M, Dunn D, Phillips A, Dooley D, Thomas A, Anderson J, Post F, Pillay D, Gazzard B, Hill T et al. J Infect Dis, 2012 Feb 15, Volume 205, Issue 4, p.540-7, (2012)
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Costagliola D, Lodwick R, Ledergerber B, Torti C, van Sighem A, Podzamczer D, Mocroft A, Dorrucci M, Masquelier B, De Luca A et al. Lancet Infect Dis, 2012 Feb, Volume 12, Issue 2, p.119-27, (2012)
Uptake and outcome of combination antiretroviral therapy in men who have sex with men according to ethnic group: the UK CHIC Study. . J Acquir Immune Defic Syndr, 2012 Apr 15, Volume 59, Issue 5, p.523-9, (2012)
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth J, van Sighem A, Kirk O, Obel N, Panos G et al. Int J Epidemiol, 2012 Apr, Volume 41, Issue 2, p.433-45, (2012)
Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. Barber T, Harrison L, Asboe D, Williams I, Kirk S, Gilson R, Bansi L, Pillay D and Dunn D. J Antimicrob Chemother, 2012 Apr, Volume 67, Issue 4, p.995-1000, (2012)
CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. Young J, Psichogiou M, Meyer L, Ayayi S, Grabar S, Raffi F, Reiss P, Gazzard B, Sharland M, Gutiérrez F et al. PLoS Med, 2012, Volume 9, Issue 3, p.e1001194, (2012)
Hepatitis B virus infection in HIV-positive individuals in the UK collaborative HIV cohort (UK CHIC) study. Price H, Bansi L, Sabin C, Bhagani S, Burroughs A, Chadwick D, Dunn D, Fisher M, Main J, Nelson M et al. PLoS One, 2012, Volume 7, Issue 11, p.e49314, (2012)
The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults. Mackie N, Dunn D, Dolling D, Garvey L, Harrison L, Fearnhill E, Tilston P, Sabin C and Geretti A. AIDS, 2013 Sep 10, Volume 27, Issue 14, p.2245-53, (2013)
HLA B*5701 status, disease progression, and response to antiretroviral therapy. . AIDS, 2013 Oct 23, Volume 27, Issue 16, p.2587-92, (2013)
Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. Dolling D, Dunn D, Sutherland K, Pillay D, Mbisa J, Parry C, Post F, Sabin C and Cane P. J Antimicrob Chemother, 2013 Oct, Volume 68, Issue 10, p.2339-43, (2013)
The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era. Mocroft A, Furrer H, Miro J, Reiss P, Mussini C, Kirk O, Abgrall S, Ayayi S, Bartmeyer B, Braun D et al. Clin Infect Dis, 2013 Oct, Volume 57, Issue 7, p.1038-47, (2013)